Steward Partners Investment Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

Steward Partners Investment Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89.1K	Buy	166 +145	+690%	+$74.3K	﹤0.01%	2646
2026 Q1	$11K	Hold	21	–	–	﹤0.01%	3512
2025 Q4	$12.2K	Buy	21 +9	+75%	+$4.6K	﹤0.01%	3362
2025 Q3	$5.5K	Buy	12 +11	+1,100%	+$4.1K	﹤0.01%	3626
2025 Q2	$303	Hold	1	–	–	﹤0.01%	4006
2025 Q1	$331	Buy	+1	New	+$329	﹤0.01%	3891
2018 Q2	–	Sell	-171	Closed	-$19K	–	2507
2018 Q1	$19K	Hold	171	–	–	﹤0.01%	1350
2017 Q4	$15K	Hold	171	–	–	﹤0.01%	1222
2017 Q3	$7K	Hold	171	–	–	﹤0.01%	1208
2017 Q2	$2K	Hold	171	–	–	﹤0.01%	1429
2017 Q1	$2K	Buy	+171	New	+$2.69K	﹤0.01%	1319

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Steward Partners Investment Advisory's MDGL Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its Madrigal Pharmaceuticals (MDGL) stake by 690% in Q2 2026, buying an estimated $74.3K and bringing the position to 166 shares worth $89.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2646.

Steward Partners Investment Advisory first reported a position in MDGL in Q1 2017 and has held it in 11 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Steward Partners Investment Advisory held 166 shares of Madrigal Pharmaceuticals worth $89.1K as of Q2 2026.
Steward Partners Investment Advisory bought 145 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $74.3K.
Madrigal Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2646 holding.
Steward Partners Investment Advisory first reported a position in Madrigal Pharmaceuticals in Q1 2017 and has held it in 11 quarters since.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.